Yusuke Kawamura

Summary

Affiliation: Toranomon Hospital
Country: Japan

Publications

  1. ncbi Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Gastroenterol 107:253-61. 2012
  2. ncbi Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 23:1739-46. 2008
  3. ncbi The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:355-60. 2008
  4. ncbi Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    AJR Am J Roentgenol 197:W665-73. 2011
  5. ncbi Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 120:1034-41. 2007
  6. ncbi Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Am J Med 123:951-956.e1. 2010
  7. ncbi Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
  8. ncbi Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
  9. ncbi Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
  10. ncbi Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007

Collaborators

Detail Information

Publications76

  1. ncbi Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Gastroenterol 107:253-61. 2012
    ....
  2. ncbi Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 23:1739-46. 2008
    ..The aim of this retrospective study was to examine the relationship between diabetes mellitus and recurrence of hepatocellular carcinoma after potentially curative therapy for hepatocellular carcinoma with nonviral hepatitis...
  3. ncbi The efficacy of short-term interferon-beta therapy for chronic hepatitis C patients with low virus load
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:355-60. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for chronic hepatitis C patients with low virus load...
  4. ncbi Heterogeneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    AJR Am J Roentgenol 197:W665-73. 2011
    ..The aim of this study was to predict recurrence of hepatocellular carcinoma (HCC) from baseline dynamic CT images...
  5. ncbi Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 120:1034-41. 2007
    ..The aim of this retrospective study was to determine the incidence of malignant lymphoma and the relationship between malignant lymphoma and viral elimination in patients with HCV...
  6. ncbi Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Am J Med 123:951-956.e1. 2010
    ..This retrospective cohort study assessed the impact of diabetes mellitus on hepatocarcinogenesis and determined the predictors of hepatocarcinogenesis in noncirrhotic, interferon-treated patients with hepatitis C virus infection...
  7. ncbi Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
    ..This study identified predictors of efficacy of PEG-IFN-RBV therapy based on viral kinetics in Japanese patients infected with HCV genotype 1b...
  8. ncbi Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
    ..The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis...
  9. ncbi Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 48:253-8. 2009
    ..The aim of this study was to evaluate the efficacy of combination therapy of peginterferon and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b and low virus load...
  10. ncbi Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
    ..026). The relative risk of HCC development in patients with BR was 0.36 compared with patients without BR. The attainment of BR during IFN therapy is effective in reducing hepatocarcinogenesis for patients with chronic HCV infection...
  11. ncbi Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
    ..10; 95% CI 1.38-3.18; P < 0.001). CONCLUSION: Our results indicate sustained virological response causes a two-thirds reduction in the risk of type 2 diabetes development in HCV-positive patients treated with IFN...
  12. ncbi Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
    ..To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response...
  13. ncbi Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1363-9. 2008
    ....
  14. ncbi HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
    Tetsuya Hosaka
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 30:1461-70. 2010
    ....
  15. ncbi Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:385-93. 2008
    ..The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear...
  16. ncbi Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:575-82. 2010
    ....
  17. ncbi A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
    ..Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV...
  18. ncbi Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    J Gastroenterol Hepatol 24:429-35. 2009
    ..However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis...
  19. ncbi Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 25:892-8. 2010
    ..To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg/day...
  20. ncbi Necessities of interferon therapy in elderly patients with chronic hepatitis C
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 122:479-86. 2009
    ..The significance of antiviral therapy for elderly patients with chronic hepatitis C virus (HCV) infection has not been elucidated...
  21. ncbi Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:1-6. 2008
    ..The aim of this study was to elucidate efficacy after dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C...
  22. ncbi Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1827-32. 2007
    ..The aim of this study was to elucidate the side effects after combination therapy of peginterferon and ribavirin for Japanese patients with chronic hepatitis C...
  23. ncbi Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients
    Hiromi Saneto
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 43:975-81. 2008
    ..The aim of this retrospective study was to determine the incidence and characteristics of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) antibody-positive elderly patients with chronic hepatitis without cirrhosis...
  24. ncbi Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 46:1357-64. 2007
    ..In multicourse IFN therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean ALT during an IFN-free period below 1.5 times the upper limit of normal...
  25. ncbi Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 83:1016-22. 2011
    ..This study emphasizes the importance of detection of aa substitutions in the core region before antiviral therapy...
  26. ncbi Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1286-92. 2007
    ..002). Our results suggest that (1) IFN and LMV are the similar effect on response, (2) IFN therapy is more effective for younger patients...
  27. ncbi Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 52:301-9. 2009
    ....
  28. ncbi Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 52:421-9. 2010
    ....
  29. ncbi Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan akuta gi umin ac jp
    Intervirology 53:188-92. 2010
    ..In treatment-resistant patients with genotype 2 chronic hepatitis C the suitable treatment duration is still unclear. The aims were to investigate extending combination therapy with peginterferon plus ribavirin for genotype 2...
  30. ncbi Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1637-43. 2008
    ..The aim of the present study was to determine the rate of hepatocarcinogenesis and the risk factor in sustained virological responders...
  31. ncbi Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Hepatology 56:2134-41. 2012
    ..The IL28B genotype might partly affect changes over time of dominant amino acid in core aa 70 of HCV-1b...
  32. ncbi Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 54:1317-24. 2009
    ..Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully...
  33. ncbi The efficacy of short-term interferon-beta therapy for type C cirrhotic patients with genotype 2a and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1085-90. 2008
    ..The aim of this study was to elucidate the efficacy of short-term interferon (IFN) therapy for type C cirrhotic patients with genotype 2a and low virus load...
  34. ncbi Suitable treatment period in patients with virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1301-7. 2008
    ..The aim of this study was to determine the suitable treatment period in patients who achieve virological response during combination therapy of peginterferon and ribavirin for chronic hepatitis C virus infection...
  35. ncbi Serum KL-6 level is elevated in chronic hepatitis C patients with combination therapy of pegylated interferon and ribavirin
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1155-60. 2007
    ..The aim of this study was to evaluate whether or not combination therapy of pegylated interferon (IFN) and ribavirin for chronic hepatitis (CH) C patients enhances the serum level of KL-6, a sensitive marker for interstitial pneumonia...
  36. ncbi Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 53:415-21. 2011
    ..With careful monitoring of anemia and prompt adjustment of RBV dose, SVR can be achieved comparably frequently between patients with CC and CA/AA genotypes...
  37. ncbi The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:265-9. 2008
    ..The aim of this study was to elucidate the efficacy of interferon (IFN) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load...
  38. ncbi Amino acid substitution in HCV core/NS5A region and genetic variation near IL28B gene affect treatment efficacy to interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:231-41. 2012
    ..To evaluate predictive factors of treatment efficacy to interferon (IFN)/ribavirin in patients infected with HCV genotype 1b (HCV-1b)...
  39. ncbi Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1032-9. 2009
    ....
  40. ncbi Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:390-5. 2010
    ..J. Med. Virol. 82:390-395, 2010. (c) 2010 Wiley-Liss, Inc...
  41. ncbi Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up
    Hiromi Yatsuji
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 48:923-31. 2008
    ..We studied the long-term efficacy (median follow-up of 28 months) of adefovir (ADV) in combination with lamivudine (LAM) in 132 LAM-resistant Japanese patients with chronic genotype C-dominant hepatitis B virus (HBV) infection...
  42. ncbi Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients
    Atsushi Ono
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 57:508-14. 2012
    ..We determined the antiviral potency and viral resistance rate after 4 years of continuous entecavir treatment in patients with chronic hepatitis B (CHB) infection...
  43. ncbi Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 84:1097-105. 2012
    ....
  44. ncbi Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 31:692-9. 2011
    ..Stage progression of 374 small hepatocellular carcinomas (HCC) was retrospectively analysed...
  45. ncbi Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo 105 8470, Japan
    World J Gastroenterol 14:5880-6. 2008
    ..To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus (HCV) positive patients...
  46. ncbi High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Cancer 115:571-80. 2009
    ..Radiofrequency ablation (RFA) has been an alternative choice for unresectable HCC. However, RFA is expected to have similar therapeutic efficacy for early stage HCC with fewer invasions...
  47. ncbi Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol l
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 46:403-10. 2007
    ..Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment...
  48. ncbi Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment
    Suguru Ogura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:179-88. 2009
    ..The aim of this study was to evaluate the impact of core aa substitutions on mortality in elderly patients...
  49. ncbi Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Med Virol 84:1593-9. 2012
    ..In conclusion, the present results suggest that IL28B genotype might partly affect viral response of HCV genotype 2 to combination therapy...
  50. ncbi Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection
    Nami Mori
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 47:1022-9. 2012
    ..The objective of this study was to elucidate the predictors of progression to hepatic decompensation during severe acute exacerbation...
  51. ncbi Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Clin Virol 54:352-4. 2012
    ..A combination therapy with two direct-acting antivirals has shown promising results in patients with HCV-1b, but the prevalence of drug-resistant variants before treatment is not known in the Japanese population...
  52. ncbi Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, 1 3 1, Kajigaya, Takatsu ku, Kawasaki, 213 8587, Japan
    J Gastroenterol 47:596-605. 2012
    ..We aimed to investigate whether these polymorphisms showed complete linkage in Japanese patients...
  53. ncbi Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intern Med 49:965-70. 2010
    ..The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 2 and high virus load...
  54. ncbi Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 1b and high virus load
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
    Intern Med 49:957-63. 2010
    ..The aim of this study was to evaluate the efficacy of combination therapy of natural human interferon-beta and ribavirin in patients infected with hepatitis C virus (HCV) genotype 1b...
  55. ncbi Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1095-102. 2007
    ..9 compared with mild or moderate fibrosis. In conclusion, long-term IFN therapy for aged patients with chronic HCV infection is effective in decreasing the serum AFP level and preventing hepatocarcinogenesis...
  56. ncbi Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Liver Int 29:736-42. 2009
    ..The advanced patterns of recurrence occasionally occur after resection. In this study, we analysed the clinical and histological characteristics of small HCC and evaluated the predictive factors of advanced tumour recurrence...
  57. ncbi Clinical and virological effects of long-term (over 5 years) lamivudine therapy
    Yoshimasa Hashimoto
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 82:684-91. 2010
    ..Moreover, after the emergence of YMDD mutants, short latency to the emergence of YMDD mutant, mixed type mutants, and low baseline ALT level were associated with elevation of ALT or viral load...
  58. ncbi The development of chronic kidney disease in Japanese patients with non-alcoholic fatty liver disease
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan
    Intern Med 50:1081-7. 2011
    ..2%. Five factors of low eGFR level, aging, type 2 diabetes, hypertension, and elevated gamma-glutamyltransferase, increases the risk of the development of CKD...
  59. ncbi Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma
    Norihiro Imai
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    Jpn J Clin Oncol 42:175-82. 2012
    ....
  60. ncbi Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 44:975-83. 2009
    ..The purpose of the study was to define the natural history of elderly patients with chronic hepatitis C needs in order to prevent HCC from arising in these patients...
  61. ncbi Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma
    Norihiro Imai
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan norihiro imai gmail com
    Oncology 80:188-94. 2011
    ..The purpose of this retrospective study was to evaluate the efficacy and safety of transcatheter arterial chemoembolization (TACE) with miriplatin in patients with unresectable hepatocellular carcinoma (HCC)...
  62. ncbi Natural human interferon beta plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus and a high viral load
    Yoshio Katamura
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 47:1827-34. 2008
    ....
  63. ncbi The efficacy of interferon-beta monotherapy for elderly patients with type C hepatitis of genotype 2
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo
    Intern Med 48:1337-42. 2009
    ..The aim of this study was to elucidate the efficacy of interferon (IFN)-beta monotherapy for elderly patients of > or = 70 years with type C hepatitis (HCV) of genotype 2...
  64. ncbi Losartan reduces the onset of type 2 diabetes in hypertensive Japanese patients with chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1584-90. 2009
    ..004), and patient had pre-diabetes (hazard ratio: 2.47; 95% confidence interval = 1.08-5.63; P = 0.032). Our results indicate losartan causes about 60% reduction of the onset of T2DM compared to patients treated with spironolactone...
  65. ncbi Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients
    Yasuji Arase
    Department of Hepatology and Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Japan
    Intern Med 50:2083-8. 2011
    ....
  66. ncbi Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection
    Tomokazu Kawaoka
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:395-401. 2007
    ..The aim of this study was to evaluate the efficacy of lamivudine therapy in elderly patients with chronic HBV infection...
  67. ncbi Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3-4A protease inhibitor telaprevir
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Clin Virol 47:76-8. 2010
    ..Although it is presently unknown whether the R130K and Q195K substitutions are related to SVR, this case suggests that long-term telaprevir monotherapy may be effective in CH-C patients with genotype 1 and a low viral load...
  68. ncbi Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    Dig Dis Sci 55:2070-6. 2010
    ..Influence of human lymphocyte antigen (HLA) on the therapeutic response in autoimmune hepatitis (AIH) is not known...
  69. ncbi Prolonged hepatitis after acute infection with genotype H hepatitis B virus
    Norio Chihara
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1847-51. 2007
    ..Genotype H, the newest type of hepatitis B, could be the type which shows a poor response to lamivudine. The present paper is the first report, describing the clinical course of acute hepatitis B with genotype H from onset to remission...
  70. ncbi Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, the Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Liver Int 27:353-9. 2007
    ..To evaluate the efficacy of temporary balloon arterial occlusion during radiofrequency ablation (RFA), randomized controlled trial was performed...
  71. ncbi New ablation procedure for a radiofrequency liver tissue coagulation system using an expandable needle
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 28:214-9. 2008
    ..The aim of this study was to investigate experimentally the efficacy of a modified extension procedure...
  72. ncbi Lipiodol and dye at the site of ablation decreases during RFA
    Miharu Hirakawa
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:362-8. 2008
    ..The aim of this study was to investigate how liver tissue could be disseminated during the RFA procedure with different devices and protocols in an in vivo porcine model...
  73. ncbi Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 80:1302-7. 2008
    ..2% at the second year, and 57.6% at the fifth year. The present study suggests that a serum albumin level of >or=3.5 g/dl and cyclic etidronate treatment reduce the appearance of bone fracture...
  74. ncbi Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Tokyo, Japan
    J Clin Virol 39:149-52. 2007
  75. ncbi Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection
    Yusuke Kawamura
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    J Gastroenterol 40:901-6. 2005
    ....
  76. ncbi [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin]
    Yusuke Kawamura
    Dept of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Gan To Kagaku Ryoho 37:402-7. 2010
    ..However, the results of our study suggested the advantage of using platinum derivatives in patients with TACE-resistant HCC...